Key result
High homocysteine is linked to ~2.7-fold higher MACE risk in premature MI.
Why the study?
Premature myocardial infarction patients face significant residual risk linked to metabolic inflammation and thrombosis. While homocysteine contributes to these processes, its synergistic effect with other metabolic risk factors on long-term prognosis had not yet been established.
Does elevated baseline plasma homocysteine (≥15 µmol/L), alone or synergistically with metabolic and inflammatory risk factors, increase the risk of long-term major adverse cardiovascular events in premature myocardial infarction patients undergoing PCI?
Cohort (n=1,220)
Does elevated baseline plasma homocysteine (≥15 µmol/L), alone or synergistically with metabolic and inflammatory risk factors, increase the risk of long-term major adverse cardiovascular events in premature myocardial infarction patients undergoing PCI?
Elevated plasma homocysteine is an independent predictor of long-term MACE in premature myocardial infarction patients and acts as a synergistic risk multiplier when combined with obesity and systemic inflammation.
High homocysteine was associated with higher MACE risk after premature MI; extends evidence on synergy with obesity and inflammation but requires prospective validation.
Background Premature myocardial infarction(PMI) patients face significant residual risk linked to metabolic inflammation and thrombosis. While homocysteine (Hcy) contributes to these processes, its synergistic effect with other metabolic risk factors on the long-term prognosis of PMI patients has not yet been established. Purpose To evaluate the independent prognostic value of Hcy on long-term MACE and to investigate its synergistic effects with metabolic and inflammatory risk factors. Methods We conducted a prospective cohort research of 1,220 consecutive PMI patients underwent percutaneous coronary intervention(PCI) (men ≤45 years, women ≤55 years) from January 2017 to December 2024. Baseline plasma Hcy was measured and categorized as either high (≥15 µmol/L) or normal (<15 µmol/L). The primary endpoint was major adverse cardiovascular events (MACE), including cardiac death, rehospitalization for severe heart failure, non-fatal myocardial infarction, ischemic stroke, readmission for unstable angina, and target lesion revascularization. Independent and synergistic associations were evaluated using multivariable Cox models and joint effect analysis. Results 136 patients (11.1%) experienced MACE over a median follow-up of 582 days. High Hcy continued to be independently linked to MACE after multivariable correction(aHR=2.72; 95%CI 1.87–3.95, P<0.001). This risk was amplified by coexisting cardiometabolic factors, increasing from a 3-to 4-fold higher risk when combined with high D-Dimer, Lp(a), or hs-CRP (aHRs 3.13-4.12), to a 6.5-fold higher risk with obesity (aHR=6.54; 95%CI 3.01-14.20, P<0.001) compared to patients with normal Hcy and normal BMI.In three-way interaction analyses, the combination of high Hcy, obesity, and elevated D-Dimer(D-Dimer>0.5mg/L) conferred a nearly 10-fold higher risk (aHR=9.91;95%CI 3.68–26.66,P<0.001), while the triad of high Hcy, obesity, and high hs-CRP(hs-CRP >2 mg/L) was associated with a 17.5-fold higher risk (aHR=17.51;95% CI 2.28–134.52,P=0.006). Conclusions In PMI patients , elevated homocysteine is an independent predictor of long-term MACE. Importantly, Hcy is a powerful "risk multiplier," increasing the negative consequences of inflammation and obesity.Our results give a clear justification for a significant upgrade in secondary prevention strategy and mechanism-driven nutritional therapies.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) conducted a cohort in Premature myocardial infarction (n=1,220). High baseline plasma homocysteine (≥15 µmol/L) vs. Normal baseline plasma homocysteine (<15 µmol/L) was evaluated on Major adverse cardiovascular events (MACE), including cardiac death, rehospitalization for severe heart failure, non-fatal myocardial infarction, ischemic stroke, readmission for unstable angina, and target lesion revascularization (aHR 2.72, 95% CI 1.87–3.95, p=<0.001). High homocysteine (≥15 µmol/L) independently increased MACE risk in premature MI (aHR 2.72; 95% CI 1.87–3.95; P<0.001) and acted synergistically with obesity and inflammation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: